Free Trial

Green Thumb Industries (OTCMKTS:GTBIF) Shares Up 4.1% - Still a Buy?

Green Thumb Industries logo with Medical background

Key Points

  • Green Thumb Industries' stock price increased by 4.1%, reaching $7.36, but trading volume was down significantly by 91% compared to the average.
  • Analysts have given GTBIF an average rating of “Buy”, with upgrades from firms including Zacks Research and Benchmark.
  • The company reported a revenue of $293.26 million for the last quarter, exceeding estimates, but missed earnings expectations with a loss of ($0.01) earnings per share.
  • Interested in Green Thumb Industries? Here are five stocks we like better.

Green Thumb Industries Inc. (OTCMKTS:GTBIF - Get Free Report)'s stock price shot up 4.1% on Tuesday . The stock traded as high as $7.36 and last traded at $7.36. 44,603 shares were traded during trading, a decline of 91% from the average session volume of 496,206 shares. The stock had previously closed at $7.07.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GTBIF. Zacks Research upgraded shares of Green Thumb Industries from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. Benchmark reiterated a "buy" rating on shares of Green Thumb Industries in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy".

View Our Latest Stock Report on GTBIF

Green Thumb Industries Trading Up 6.6%

The business's 50-day moving average is $7.30 and its two-hundred day moving average is $6.20. The firm has a market cap of $1.60 billion, a P/E ratio of 68.55 and a beta of 1.22.

Green Thumb Industries (OTCMKTS:GTBIF - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.05). Green Thumb Industries had a net margin of 2.51% and a return on equity of 1.62%. The business had revenue of $293.26 million for the quarter, compared to the consensus estimate of $280.66 million. On average, analysts anticipate that Green Thumb Industries Inc. will post 0.32 earnings per share for the current year.

Green Thumb Industries Company Profile

(Get Free Report)

Green Thumb Industries Inc manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Green Thumb Industries Right Now?

Before you consider Green Thumb Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Green Thumb Industries wasn't on the list.

While Green Thumb Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.